Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Thursday.

Several other analysts also recently weighed in on the company. Credit Suisse Group AG set a $145.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, September 30th. FBR & Co restated an “outperform” rating and set a $180.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, July 17th. Jefferies Group restated a “buy” rating and set a $80.00 target price (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, June 8th. Zacks Investment Research downgraded Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 25th. Finally, Morgan Stanley started coverage on Alnylam Pharmaceuticals in a research note on Tuesday, August 2nd. They set an “overweight” rating and a $93.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $106.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 70.30 on Thursday. The company’s market capitalization is $6.03 billion. The company’s 50-day moving average price is $72.86 and its 200-day moving average price is $66.46. Alnylam Pharmaceuticals has a 52 week low of $49.96 and a 52 week high of $110.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same quarter in the prior year, the company earned ($0.85) EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.64) EPS for the current fiscal year.

In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ALNY. Dodge & Cox purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $139,650,000. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the period. Bridger Management LLC purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $50,041,000. Slate Path Capital LP boosted its stake in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock valued at $71,244,000 after buying an additional 410,000 shares during the period. Finally, Deerfield Management Co. purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $18,645,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.